microRNA-122与非酒精性脂肪性肝病研究进展*

doi:10.3969/j.issn.1672-5069.2024.05.002

摘要/Abstract

Key words: Non-alcoholic fatty liver disease, MicroRNA-122, Progress

贾双珍, 吴天威, 吴捷. microRNA-122与非酒精性脂肪性肝病研究进展^*[J]. 实用肝脏病杂志, 2024, 27(5): 646-649.

Jia Shuangzhen, Wu Tianwei, Wu Jie. MicroRNA-122 in non-alcoholic fatty liver disease[J]. Journal of Practical Hepatology, 2024, 27(5): 646-649.

[1] Han SK, Baik SK, Kim MY. Non-alcoholic fatty liver disease: definition and subtypes. Clin Mol Hepatol, 2023, 29(Suppl): S5-S16.
[2] Paternostro R, Trauner M. Current treatment of non-alcoholic fatty liver disease. J Intern Med, 2022, 292(2): 190-204.
[3] Zhou J, Zhou F, Wang W, et al. Epidemiological features of NAFLD from 1999 to 2018 in China. Hepatology, 2020, 71(5): 1851-1864.
[4] Nassir F. NAFLD: mechanisms, treatments, and biomarkers. Biomolecules, 2022, 12(6): 824.
[5] Powell EE, Wong VWS, Rinella M. Non-alcoholic fatty liver disease. Lancet, 2021, 397(10290): 2212-2224.
[6] Lu TX, Rothenberg ME. MicroRNA. J Allergy Clin Immun, 2018, 141(4): 1202-1207.
[7] Mohr A, Mott J. Overview of microRNA biology. Semin Liver Dis, 2015, 35(1): 003-011.
[8] Ho PTB, Clark IM, Le LTT. MicroRNA-based diagnosis and therapy. Int J Mol Sci, 2022, 23(13): 7167.
[9] Bayraktar E, Bayraktar R, Oztatlici H, et al. Targeting miRNAs and other non-coding RNAs as a therapeutic approach: an update. Non-Coding RNA, 2023, 9(2): 27.
[10] Long JK, Dai W, Zheng YW, et al. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease. Mol Med, 2019, 25(1): 26.
[11] Wang X, He Y, Mackowiak B, et al. MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases. Gut, 2021, 70(4): 784-795.
[12] Kunden RD, Khan JQ, Ghezelbash S, et al. The role of the liver-specific microRNA, miRNA-122 in the HCV replication cycle. Int J Mol Sci, 2020, 21(16): 5677.
[13] Möröy T, Etiemble J, Bougueleret L, et al. Structure and expression of hcr, a locus rearranged with c-myc in a woodchuck hepatocellular carcinoma. Oncogene, 1989, 4(1): 59-65.
[14] Faramin Lashkarian M, Hashemipour N, Niaraki N, et al. MicroRNA-122 in human cancers: from mechanistic to clinical perspectives. Cancer Cell Int, 2023, 23(1): 29.
[15] Chien Y, Chang YL, Li HY, et al. Synergistic effects of carboxymethyl-hexanoyl chitosan, cationic polyurethane-short branch PEI in miR122 gene delivery: Accelerated differentiation of iPSCs into mature hepatocyte-like cells and improved stem cell therapy in a hepatic failure model. Acta Biomater, 2015, 13: 228-244.
[16] Parvanak M, Mostafavi-Pour Z, Soleimani M, et al. Mir-122 upregulation and let-7f downregulation combination: The effects on hepatic differentiation of hiPSCs on the PCL-Gel-HA nanofibrous scaffold. J Cell Mol Med, 2022, 26(20): 5235-5245.
[17] Gatfield D, Le Martelot G, Vejnar CE, et al. Integration of microRNA miR-122 in hepatic circadian gene expression. Gene Dev, 2009, 23(11): 1313-1326.
[18] Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. Adv Cancer Res, 2021, 149: 1-61.
[19] Zhao Z, Gao J, Huang S. LncRNA SNHG7 promotes the HCC progression through miR-122-5p/FOXK2 axis. Digest Dis Sci, 2022, 67(3): 925-935.
[20] Ouahed J, Spencer E, Kotlarz D, et al. Very early onset inflammatory bowel disease: a clinical approach with a focus on the role of genetics and underlying immune deficiencies. Nes Nutr Ws, 2020, 26(6): 820-842.
[21] Wei X, Liu H, Li X, et al. Over-expression ofmiR-122 promotes apoptosis of hepatocellular carcinoma via targeting TLR4. Ann Hepatol, 2019, 18(6): 869-878.
[22] Hochreuter MY, Dall M, Treebak JT, et al. MicroRNAs in non-alcoholic fatty liver disease: progress and perspectives. Mol Metab, 2022, 65: 101581.
[23] Xu H, Xu SJ, Xie SJ, et al. MicroRNA-122 supports robust innate immunity in hepatocytes by targeting the RTKs/STAT3 signaling pathway. eLife, 2019, 8: e41159.
[24] Janssen HLA, Reesink HW, Lawitz EJ, et al. Treatment of HCV infection bytargeting MicroRNA. N Engl J Med, 2013, 368(18): 1685-1694.
[25] Johri MK, Lashkari HV, Gupta D, et al. mTORC1 restricts hepatitis C virus RNA replication through ULK1-mediated suppression of miR-122 and facilitates post-replication events. J Gen Virol, 2020, 101(1): 86-95.
[26] Li A, Wu J, Zhai A, et al. HBV triggers APOBEC2 expression through miR-122 regulation and affects the proliferation of liver cancer cells. Int J Oncol, 2019, 55(5): 1137-1148.
[27] Hu Y, Du G, Li G, et al. The miR-122 inhibition alleviates lipid accumulation and inflammation in NAFLD cell model. Arch Physiol Biochem, 2021, 127(5): 385-389.
[28] Dong L, Hou X, Liu F, et al. Regulation of insulin resistance by targeting the insulin-like growth factor 1 receptor with microRNA-122-5p in hepatic cells. Cell Biol Int, 2019, 43(5): 553-564.
[29] Krützfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature, 2005, 438(7068): 685-689.
[30] Esau C, Davis S, Murray SF, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab, 2006, 3(2): 87-98.
[31] Csak T, Bala S, Lippai D, et al. microRNA-122 regulates hypoxia-inducible factor-1 and vimentin in hepatocytes and correlates with fibrosis in diet-induced steatohepatitis. Liver Int, 2015, 35(2): 532-541.
[32] Wang L, Tang W, Yan S, et al. Efficient delivery of miR-122 to regulate cholesterol metabolism using a non-covalent peptide-based strategy. Mol Med Rep, 2013, 8(5): 1472-1478.
[33] Yamada H, Ohashi K, Suzuki K, et al. Longitudinal study of circulating miR-122 in a rat model of non-alcoholic fatty liver disease. Clin Chim Acta, 2015, 446: 267-271.
[34] Atic AI, Thiele M, Munk A, et al. Circulating miRNAs associated with nonalcoholic fatty liver disease. Am J Physiol Cell Physiol, 2023, 324(2): C588-C602.
[35] Pirola CJ, Fernández Gianotti T, Castaño GO, et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut, 2014, 64(5): 800-812.
[36] 童静, 张珂瓈, 李昌平. 非酒精性脂肪性肝炎患者血清前神经降压素和微小RNA-122水平变化及其诊断脂肪性肝炎的价值探讨. 实用肝脏病杂志, 2024, 27(2): 202-205.
[37] 胡灵溪, 安薪宇, 李妹, 等. 超声衰减参数诊断体检人群脂肪肝临床应用价值分析. 实用肝脏病杂志, 2023, 26(4): 488-491.
[38] Salvoza NC, Klinzing DC, Gopez-Cervantes J, et al. Association of circulating serum miR-34a and miR-122 with dyslipidemia among patients with non-alcoholic fatty liver disease. PLoS One, 2016, 11(4): e0153497.
[39] Wu GY, Rui C, Chen JQ, et al. MicroRNA-122 inhibits lipid droplet formation and hepatic triglyceride accumulation via Yin Yang 1. Cell Physiol Biochem, 2017, 44(4): 1651-1664.
[40] Zhang X, Ma L, Zhai L, et al. Construction and validation of a three-microRNA signature as prognostic biomarker in patients with hepatocellular carcinoma. Int J Med Sci, 2021, 18(4): 984-999.
[41] Leti F, Malenica I, Doshi M, et al. High-throughput sequencing reveals altered expression of hepatic microRNAs in nonalcoholic fatty liver disease-related fibrosis. Transl Res, 2015, 166(3): 304-314.
[42] Chai C, Cox B, Yaish D, et al. Agonist of RORA attenuates nonalcoholic fatty liver progression in mice via up-regulation of microRNA 122. Gastroenterology, 2020, 159(3): 999-1014,e9.

microRNA-122与非酒精性脂肪性肝病研究进展^*

MicroRNA-122 in non-alcoholic fatty liver disease

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李艳敏, 张维, 胡彦彦, 齐蕾. 老年非酒精性脂肪性肝病合并2型糖尿病患者血清TyG、内脏/皮下脂肪面积比和心脏代谢指数变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2024, 27(5): 697-700.
[2]	中华医学会肝病学分会. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 实用肝脏病杂志, 2024, 27(4): 494-510.
[3]	李开楊, 赵琦, 黄敬, 唐云, 蔺晓源, 刘杰民, 杨梅. 中国临床试验注册中心注册的非酒精性脂肪性肝病临床试验特征分析^*[J]. 实用肝脏病杂志, 2024, 27(4): 531-534.
[4]	农晓黎, 陈菲, 詹浩洪, 罗婷, 曾碧丹. 体检人群非酒精性脂肪性肝病发病率及其相关危险因素分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 353-356.
[5]	孙世磊, 刘翠翠, 李曙光, 鲁科翔. 非酒精性脂肪性肝病合并T2DM患者血清成纤维细胞生长因子-21和分泌型卷曲相关蛋白5水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2024, 27(3): 357-360.
[6]	高洋, 张静, 卢宣霖. 非酒精性脂肪性肝病患者血清IL-1RA、CTRP13和CK-18水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2024, 27(2): 185-188.
[7]	郭萌, 郭琦, 张峰. 超声瞬时弹性成像检测受控衰减参数评估非酒精性脂肪性肝病患者肝脂肪变程度价值研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 189-192.
[8]	李敏, 张丽, 曾艾, 刘世裕. 2型糖尿病合并非酒精性脂肪性肝病患者肝纤维化检出率及预测因素分析^*[J]. 实用肝脏病杂志, 2024, 27(2): 193-197.
[9]	郑波, 哈丽达·夏尔甫哈孜, 谈理. 非酒精性脂肪性肝病患者血清HIF-1α、HMGB1和脂联素水平变化及其与颈动脉粥样硬化的关系研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 198-201.
[10]	童静, 张珂瓈, 李昌平. 非酒精性脂肪性肝炎患者血清前神经降压素和微小RNA-122水平变化及其诊断脂肪性肝炎的价值探讨^*[J]. 实用肝脏病杂志, 2024, 27(2): 202-205.
[11]	黄洁杰, 郑倩, 吕睿, 王瑞萍. 利拉鲁肽联合阿托伐他汀钙治疗伴有糖脂代谢异常的非酒精性脂肪性肝病患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(1): 36-39.
[12]	王文川, 梁阔鹏, 何蕊玲, 王继涛, 吉晓林, 刘成禹, 张宣哲, 张清格, 郭海军, 张健, 高华方, 郑少阳, 祁小龙, 刘登湘. 社区2型糖尿病合并NAFLD患病流行率调查^*[J]. 实用肝脏病杂志, 2024, 27(1): 40-43.
[13]	蔺宁, 孔明, 段钟平. 非酒精性脂肪性肝病营养干预研究进展^*[J]. 实用肝脏病杂志, 2024, 27(1): 151-154.
[14]	曾静, 范建高. 代谢相关脂肪性肝病自然史研究进展[J]. 实用肝脏病杂志, 2023, 26(6): 769-772.
[15]	周季颖, 谢月红, 于翠霞. 恩替卡韦治疗慢性乙型肝炎合并非酒精性脂肪性肝病患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 793-796.